Table 2.
Cox proportional hazard ratios for time to event from estimated date of HIV-1 infection among cohort participants with human leukocyte antigena data, n = 491.
| 2a: Time to CD4+ cell count ≤350 cells/μl | 2b: Time to viral load ≥1 × 105 copies/ml | 2c: Time to AIDSb | ||||||||||||||||||||
| Unadjusted analysis | Adjusted analysis | Unadjusted analysis | Adjusted analysis | Unadjusted analysis | Adjusted analysis | |||||||||||||||||
| Characteristic | n | events | HRc | 95% CId | P | HR | 95% CI | P | Events | HR | 95% CI | P | HR | 95% CI | P | Events | HR | 95% CI | P | HR | 95% CI | P |
| Age at EDIe (years) | ||||||||||||||||||||||
| <40 | 416 | 167 | 1 | – | – | 1 | – | – | 151 | 1 | – | – | 1 | – | – | 134 | 1 | – | – | 1 | – | – |
| ≥40 | 75 | 41 | 1.46 | (1.04, 2.05) | 0.03 | 1.35 | (0.94, 1.93) | 0.11 | 36 | 1.40 | (0.97, 2.01) | 0.07 | 1.12 | (0.77, 1.63) | 0.56 | 34 | 1.40 | (0.96, 2.04) | 0.08 | 1.43 | (0.96, 2.12) | 0.08 |
| Sex | ||||||||||||||||||||||
| Women | 200 | 75 | 1 | – | – | 1 | – | – | 53 | 1 | – | – | 1 | – | – | 56 | 1 | – | – | 1 | – | – |
| Non-MSMf | 232 | 111 | 1.43 | (1.06, 1.91) | 0.02 | 1.32 | (0.97, 1.79) | 0.08 | 115 | 2.15 | (1.55, 2.98) | <0.001 | 2.10 | (1.51, 2.93) | <0.001 | 87 | 1.43 | (1.02, 2.00) | 0.04 | 1.36 | (0.96, 1.91) | 0.09 |
| MSM | 59 | 22 | 1.10 | (0.68, 1.77) | 0.70 | 1.23 | (0.75, 2.03) | 0.41 | 19 | 1.31 | (0.78, 2.22) | 0.31 | 1.49 | (0.86, 2.60) | 0.14 | 25 | 1.94 | (1.21, 3.12) | 0.006 | 2.42 | (1.47, 3.99) | <0.001 |
| HLA B*57 allele | ||||||||||||||||||||||
| No | 450 | 195 | 1 | – | – | 1 | – | – | 179 | 1 | – | – | 1 | – | – | 162 | 1 | – | – | 1 | – | – |
| Yes | 41 | 13 | 0.60 | (0.34, 1.05) | 0.07 | 0.60 | (0.34, 1.06) | 0.08 | 8 | 0.38 | (0.19, 0.78) | 0.008 | 0.39 | (0.19, 0.79) | 0.009 | 6 | 0.30 | (0.13, 0.68) | 0.004 | 0.30 | (0.13, 0.69) | 0.004 |
| HLA B*45 allele | ||||||||||||||||||||||
| No | 415 | 164 | 1 | – | – | 1 | – | – | 150 | 1 | – | – | 1 | – | – | 138 | 1 | – | – | 1 | – | – |
| Yes | 76 | 44 | 1.71 | (1.22, 2.39) | 0.002 | 1.60 | (1.14, 2.25) | 0.007 | 37 | 1.58 | (1.10, 2.27) | 0.01 | 1.47 | (1.01, 2.14) | 0.04 | 30 | 1.48 | (0.99, 2.20) | 0.05 | 1.33 | (0.89, 1.99) | 0.16 |
| HIV-1 subtype | ||||||||||||||||||||||
| A | 177 | 65 | 1 | – | – | 1 | – | – | 53 | 1 | – | – | 1 | – | – | 50 | 1 | – | – | 1 | – | – |
| C | 243 | 117 | 1.58 | (1.16, 2.14) | 0.003 | 1.60 | (1.16, 2.20) | 0.004 | 105 | 1.57 | (1.13, 2.19) | 0.008 | 1.59 | (1.12,2.25) | 0.009 | 88 | 1.41 | (0.99, 2.00) | 0.05 | 1.60 | (1.11, 2.31) | 0.01 |
| D | 71 | 26 | 1.05 | (0.67, 1.65) | 0.84 | 1.04 | (0.65, 1.66) | 0.87 | 29 | 1.46 | (1.00, 2.46) | 0.05 | 1.61 | (1.01, 2.57) | 0.05 | 30 | 1.81 | (1.15, 2.85) | 0.01 | 1.93 | (1.21, 3.09) | 0.006 |
aHLA, human leukocyte antigen.
b1993 CDC Case Definition; majority of endpoints were CD4+ cell count ≤200 cells/μl.
cHR, hazard ratio.
dCI, confidence interval.
eEDI, estimated date of infection.
fNon-MSM: a male who does not report sex with men.